Click to download or view mobile version

Author(s):

Duvuru Geetha¹, Frank B. Cortazar², Annette Bruchfeld³, Alexandre Karras⁴, Peter A. Merkel⁵, David R.W. Jayne⁶ for the ADVOCATE Study Group

¹Johns Hopkins University, Baltimore, MD, USA; ²St. Peter’s Hospital, Albany, NY, USA; ³Karolinska Institutet, Stockholm, Stockholm, Sweden; Linköpings Universitet, Linkoping, Östergötland, Sweden; ⁴Université Paris Cité, Paris, Île-de-France, France; ⁵University of Pennsylvania, Philadelphia, PA, USA; ⁶University of Cambridge, Cambridge, UK

Abstract or description:

A US Patient Perspective on the Diagnosis and Burden of AxSpA

Safety of a JAKi Across 15,000 Patient-Years of Data

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies

ADD THE FIRST COMMENT

If you are a health practitioner, you may Login/Register to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Topics

Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients With Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

A US Patient Perspective on the Diagnosis and Burden of AxSpA

Safety of a JAKi Across 15,000 Patient-Years of Data

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies

ADD THE FIRST COMMENT

Do you get our email newsletter?